Carboplatin and Celecoxib for Ovarian Cancer
Author Information
Author(s): Francesco Legge, Amelia Paglia, Marco D'Asta, Gilda Fuoco, Giovanni Scambia, Gabriella Ferrandina
Primary Institution: Catholic University of Campobasso, Italy
Hypothesis
The combination of carboplatin and celecoxib will show antitumor activity and safety in heavily pre-treated recurrent ovarian cancer patients.
Conclusion
Celecoxib combined with carboplatin showed promising activity and it is well tolerated in heavily-treated recurrent ovarian cancer patients.
Supporting Evidence
- Overall response rate was 28.9% with 3 complete and 10 partial responses.
- Median progression-free survival was 5 months and overall survival was 13 months.
- Only one case of grade 4 toxicity was observed, indicating good tolerability.
Takeaway
This study tested a new treatment for women with recurring ovarian cancer, and it showed that the combination of two drugs can help some patients feel better.
Methodology
Patients received oral celecoxib and intravenous carboplatin, with response rates assessed using RECIST criteria.
Potential Biases
Potential biases due to the non-sponsored, investigator-initiated nature of the study.
Limitations
The study had a small sample size and was not randomized.
Participant Demographics
Median age was 59 years, with 76.7% having serous histotype and 51.1% presenting platinum-resistance.
Statistical Information
P-Value
0.11
Statistical Significance
p=0.11
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website